Estrategias de manejo de terapias de alta eficacia para esclerosis múltiple en la práctica clínica

Abstract

Introduction

There are currently a significant number of options for disease-modifying therapies in multiple sclerosis (MS), which can be categorized as low, moderate, or highly effective based on their ability to control disease activity. As there are few comparative studies between high-efficacy therapies (HET), there is uncertainty about the best time to indicate or replace them.

Objective

To assist treating physicians in making decisions about the choice and use of highly effective therapies, in different scenarios regarding persistence of activity, progression of disability, presence of poor prognostic factors, or adverse effects under treatment.

Comments

A group of Argentine neurologists with experience in the management of patients with MS was convened to discuss and identify valid options for the strategy of indications and management of HETs (cladribine, ocrelizumab, ofatumumab, natalizumab, and alemtuzumab).

Conclusions

This work aims to serve as a guide for treating physicians in case of doubts about the management of SAD, according to what they would do in their office referring to the management of MS in Argentina.